Rybelsus — oral semaglutide in tablet form: price, side effects and weight loss

01 Mar

Rybelsus is the world’s first GLP-1 drug in tablet form. Same active substance as in Ozempic — semaglutide — but without injections. For those who want to take advantage of semaglutide’s appetite-suppressing effect but prefer to avoid injections, Rybelsus appears to be an attractive alternative. We go through how the tablet works, how much it costs in Sweden, what weight loss you can expect and which side effects are most common — including questions about alcohol and fatigue.

How Rybelsus works — semaglutide as a tablet

Rybelsus contains semaglutide in combination with an absorption enhancer called SNAC (sodium salcaprozate). SNAC protects the semaglutide molecule from breakdown in the stomach and helps it pass through the stomach lining into the bloodstream. Without SNAC, stomach acid would break down the peptide before it could be absorbed — which is why GLP-1 drugs have historically only been available as injections.

Once in the blood, semaglutide works in exactly the same way regardless of whether it got there via a tablet or a syringe. The substance binds to GLP-1 receptors and suppresses appetite, slows gastric emptying and improves the body’s insulin response after a meal. The difference lies in bioavailability — the proportion of the substance that actually reaches the bloodstream. When administered orally, bioavailability is only about 1%, compared to close to 90% when injected subcutaneously. This explains why Rybelsus is dosed in milligrams (7–14 mg) while Ozempic is dosed in less than one milligram (0.5–1 mg).

The low absorption also places specific requirements on how you take the tablet. Rybelsus must be swallowed on an empty stomach with a maximum of half a glass of water — no more. Then you wait at least 30 minutes before eating, drinking or taking other medicines. If you break these rules, the uptake drops drastically and the effect is weakened. Even drinking coffee during the waiting period can negatively affect absorption. The strict routine is the price you pay to avoid injections, and it’s worth being honest with yourself: can you handle waiting half an hour every morning before breakfast? If the answer is no, injectable semaglutide may be more reliable in practice.

Rybelsu’s weight loss — what does the research say?

Rybelsus is formally approved for type 2 diabetes, not weight loss. However, weight loss is a well-documented secondary effect. In the PIONEER studies, patients with diabetes lost an average of 4-5 kg ​​on the 14 mg dose over 26 weeks. This corresponds to approximately 4-5% of body weight.

Compared to injectable semaglutide (Ozempic/Wegovy), weight loss with Rybelsus is more limited. Ozempic typically produces 8-12% weight loss, and Wegovy reaches 15% at optimal dosage. The reason is precisely the lower bioavailability — even though the tablet contains more semaglutide in absolute terms, a smaller percentage reaches the bloodstream.

This makes Rybelsus best suited for people who want moderate appetite suppression and weight loss without injections, rather than the maximum effect that injectables offers. Some patients start with Rybelsus and later switch to Ozempic or Wegovy if they need more significant weight loss — the escalation from tablet to injection is often experienced as smoother than starting directly with injections. The body has already gotten used to semaglutide, and the side effects when switching are therefore often milder.

It is also worth mentioning that individual variation is large. Some patients lose 7-8% of their body weight on Rybelsus 14 mg, while others barely notice a difference. Genetic factors, how strictly you follow the dosing routine and your diet all come into play. Rybelsus is not a miracle cure — it is a tool that works best in combination with conscious dietary choices and regular physical activity.

During 2024–2025, Novo Nordisk conducted the OASIS 1 study with oral semaglutide at the higher dose of 50 mg (not yet approved) specifically for weight loss. The results showed an average weight loss of about 15% — on par with injectable Wegovy. If the 50 mg dose is approved, it could change the entire landscape of oral weight loss therapy. But currently (2026) the maximum dose is 14 mg.

Rybelsu side effects — nausea, fatigue and gastrointestinal upset

The side effect profile is similar to that of injectable semaglutide, with the gastrointestinal tract being the most affected area. The most commonly reported side effects in the PIONEER studies:

• Nausea — about 15-20% of the 14 mg dose, milder than with injectable semaglutide

• Diarrhea — around 10–12%, usually transient in the first few weeks

• Decreased appetite — 7-9%, the “desired side effect” for many

• Vomiting — about 8%, most common with dose increase

• Constipation — 5-7%, may require increased fiber and fluid intake

• Abdominal pain — about 5–7%, linked to the altered gastric emptying

Dizziness and fatigue

Fatigue is not mentioned as a primary side effect in the SmPC (FASS), but is reported by a significant proportion of users in patient forums and clinical practice. The reason is probably multifactorial: the reduced caloric intake gives the body less energy to work with, the blood sugar fluctuations may be different from what the body is used to, and the altered intestinal rhythm may affect the general condition. Most people experience that the fatigue subsides after 3-4 weeks when the body has adapted to the lower calorie intake. If fatigue persists, discuss the dose with your prescriber — sometimes it helps to stay on 7 mg for an extra month before increasing to 14 mg. Also make sure you’re getting enough protein and micronutrients — with reduced food intake, it’s easy to fall short.

Rybelsus and alcohol

Alcohol is not mentioned as a specific contraindication to Rybelsus, but there are practical reasons for caution. Semaglutide lowers blood sugar — alcohol does the same. The combination can cause unexpectedly low blood sugar, especially if you drink on an empty stomach. Alcohol also delays gastric emptying further, which can increase nausea. Our recommendation: avoid alcohol during the ramp-up phase and then be moderate. A glass of wine with dinner is rarely a problem for most people, but drinking on an empty stomach or in large quantities should be avoided.

Rybelsus price in Sweden — cost and subsidy

Rybelsus is subsidized in Sweden for patients with type 2 diabetes who meet specific criteria. The price per package (30 tablets) is at the following levels in 2026:

|Dose|Price per pack (approx)|Monthly cost|

|3 mg (starting dose)|~ SEK 900|~ SEK 900|

|7 mg (maintenance dose)|~ SEK 1,100|~ SEK 1,100|

|14 mg (max dose)|~ SEK 1,300|~ SEK 1,300|

With the drug benefit, you pay significantly less — after the high-cost protection, a maximum of SEK 2,600 per twelve-month period for all your prescription drugs. Without a benefit (for example in the case of off-label use for weight loss only) you pay the full amount. The annual cost of 14 mg without subsidy ends up around SEK 15,000-16,000, which makes Rybelsus one of the cheaper alternatives to Ozempic — but you also get a slightly weaker weight loss effect compared to the injections.

Rybelsus according to FASS — what is in the product summary?

The FASS text for Rybelsus specifies the indication as treatment of inadequately controlled type 2 diabetes in adults, as an adjunct to diet and exercise. The preparation can be used as monotherapy (when metformin is not tolerated) or in combination with other diabetes medicines.

The dosage according to FASS: starting dose of 3 mg daily for at least one month, then increase to 7 mg. If necessary, the dose can be increased to 14 mg after at least another month. FASS emphasizes that the tablet should be taken on an empty stomach, swallowed whole with no more than half a glass of water, and that the patient should wait at least 30 minutes before food and other medicines.

Contraindications according to the summary of product include hypersensitivity to semaglutide, pregnancy and lactation. Caution should be exercised in history of pancreatitis, diabetic retinopathy and severe renal failure. FASS also lists that weight loss with semaglutide varies by individual and is not guaranteed — an important fact that is sometimes glossed over in media reporting.

Are you considering switching from tablets to injections? Switching from Rybelsus 14 mg to Ozempic 0.5 mg can be done directly without escalation, according to FASS. The escalation to the full dose of Ozempic (1 mg) then takes place according to the regular schedule.

.entry-content